Utilization of the Impella for hemodynamic support during percutaneous intervention and cardiogenic shock: an insight. (3rd October 2017)

• Record Type: Journal Article
• Authors: Nalluri, Nikhil; Patel, Nileshkumar; Saouma, Samer; Anugu, Viswajit Reddy; Anugula, Dixitha; Asti, Deepak; Mehta, Varshil; Kumar, Varun; Atti, Varunsiri; Edla, Sushruth; Grewal, Rasleen K.; Khan, Hafiz M.; Kanotra, Ritesh; Maniatis, Gregory; Kandov, Ruben; Lafferty, James C.; Dyal, Michael; Alfonso, Carlos E.; Cohen, Mauricio G.
• Is Part Of: Expert review of medical devices. Volume 14:Number 10(2017)
• Page Start: 789
• Page End: 804
• Publication Date: 2017-10-03
• Subjects: Percutaneous coronary interventions: PCI -- mechanical circulatory support: MCS -- high-risk percutaneous coronary interventions: HRPCI -- cardiogenic shock: CS -- refractory cardiac arrest: RCA -- intra-aortic balloon pump: IABP -- percutaneous ventricular assist device: pVAD -- acute myocardial infarction with cardiogenic shock: AMICS; Medical instruments and apparatus -- Periodicals; 610.28
• DOI: 10.1080/17434440.2017.1374849
• Languages: English
• ISSNs: 1743-4440

Abstract

ABSTRACT: Introduction: Impella is a catheter-based micro-axial flow pump placed across the aortic valve, and it is currently the only percutaneous left ventricular assist device approved for high-risk percutaneous coronary intervention and cardiogenic shock. Areas Covered: Even though several studies have repeatedly demonstrated the excellent hemodynamic profile of Impella in high-risk settings, it remains underutilized. Here we aim to provide an up-to-date summary of the available literature on Impellas use in High risk settings as well as the practical aspects of its usage. Expert Commentary: Percutaneous coronary interventions in high rsk settings have always been challenging for a physician. Impella 2.5 and CP, have been proven safe, cost effective and feasible in High Risk Percutaneous coronary Interventions with an excellent hemodynamic profile.